附带致死性:在癌症中是一种独特的合成致死性
Zichen Zhao1, Lingling Zhu1, Yu Luo2
1Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, China.
利用癌症的遗传脆弱性,如合成和附带致死性,提供了新的治疗策略. 研究重点是确定基因相互作用以开发向抗瘤药物,特别是针对瘤抑制基因 (TSG) 缺陷的瘤.
科学领域:
- 在瘤学瘤学.
- 癌症遗传学 癌症遗传学
- 分子生物学分子生物学
背景情况:
- 瘤抑制基因 (TSG) 和瘤基因在癌症发育中通过功能增益和丧失突变至关重要.
- 缺少TSG的瘤对补偿途径抑制的敏感性增加,造成治疗脆弱性.
- 合成致死性和附带致死性是针对癌症特异性遗传缺陷的关键策略.
研究的目的:
- 讨论针对癌症特异性TSG删除或失活的治疗策略.
- 审查现有的查和识别潜在的基因相互作用伙伴的方法.
- 突出针对个性化癌症治疗的临床前附带死亡率研究的进展和挑战.
主要方法:
- 审查涉及TSG失活的概念治疗策略.
- 讨论用于识别基因相互作用伙伴的查方法.
- 对癌症附带死亡率的临床前数据的分析.
主要成果:
- 合成致死性是临床验证的;附带致死性主要是临床前的.
- 对癌症基因组进行基因相互作用的查是一种有前途的药物开发方法.
- 附带致命性利用TSG附近的共同删除的乘客基因.
结论:
- 附带致死性为新型抗瘤疗法提供了一个有希望的途径,尽管临床翻译面临挑战.
- 识别基因相互作用对于开发个性化癌症疗法至关重要.
- 需要对附带致死性进行进一步的研究,以克服临床前到临床翻译的障碍.
更多相关视频
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
